Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (CMML/AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02807272
Recruitment Status : Recruiting
First Posted : June 21, 2016
Last Update Posted : October 16, 2019
Sponsor:
Information provided by (Responsible Party):
Kura Oncology, Inc.

Brief Summary:
A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 36 eligible subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN), including Chronic Myelomonocytic Leukemia (CMML), and 36 eligible subjects with Acute Myeloid Leukemia (AML). Subjects (amendment 3 Cohorts 1-4) will receive tipifarnib administered at a dose of 400 mg, orally with food, twice a day (bid) for 21 days in 28 day cycles.

Condition or disease Intervention/treatment Phase
Leukemia, Myelomonocytic, Chronic Drug: Tipifarnib Phase 2

Detailed Description:

This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with Myelodysplastic/Myeloproliferative Neoplasias (MDS/MPN cohorts) and Acute Myeloid Leukemia (AML cohorts). For MDS/MPN cohorts, this study will assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with MDS/MPN, including CMML, who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with a low CXCR4/2 ratio. For AML cohorts, this study will assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with AML who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with low CXCR4/2 ratio. Subjects enrolled in the study will consist of patients with KRAS, NRAS wild type status.

  1. Subjects with MDS/MPN with high CXCR4/2 ratio
  2. Subjects with MDS/MPN with low CXCR4/2 ratio
  3. Subjects with AML with high CXCR4/2 ratio
  4. Subjects with AML with low CXCR4/2 ratio

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia
Study Start Date : October 2016
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : May 2022


Arm Intervention/treatment
Experimental: Tipifarnib, Oral
Single arm
Drug: Tipifarnib
Oral tablet
Other Names:
  • R115777
  • Zarnestra




Primary Outcome Measures :
  1. To assess the antitumor activity of tipifarnib in CMML subjects [ Time Frame: 1 year ]
    To assess the antitumor activity of tipifarnib, in terms of Objective Response Rate (ORR), in subjects with CMML and in subjects with CMML whose disease is KRAS/NRAS wild type.

  2. To assess the antitumor activity of tipifarnib in MDS/MPN subjects [ Time Frame: 1 year ]
    To assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with MDS/MPN, including CMML, who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with low CXCR4/2 ratio.

  3. To assess the antitumor activity of tipifarnib in AML subjects [ Time Frame: 1 year ]
    To assess the antitumor activity of tipifarnib, in terms of ORR, in subjects with AML who have a high ratio of expression of CXCR4 to CXCR2 (CXCR4/2 ratio) in their bone marrow and in those with low CXCR4/2 ratio.


Secondary Outcome Measures :
  1. Rate of complete response (CR) [ Time Frame: 1 year ]
    To assess the effect of tipifarnib on rate of complete response, complete cytogenetic remission, partial remission, marrow response, and clinical benefit

  2. Duration of Response [ Time Frame: 1 year ]
    To assess the effect of tipifarnib on duration of response.

  3. Rate of progression free survival (PFS) at 1 year [ Time Frame: 1 year ]
    To assess the effect of tipifarnib on rate of progressive free survival at 1 year.

  4. Rate of survival at 1 year [ Time Frame: 1 year ]
    To assess the effect of tipifarnib on rate of survival at 1 year.

  5. Adverse event (AE) profile [ Time Frame: Until 30 days following end of study ]
    To assess the effect of tipifarnib on adverse event (AE) profile according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v 4.03).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is at least 18 years of age.
  2. For subjects to be enrolled in the CMML or MDS/MPN cohorts:

    a. Diagnosis of CMML or MDS/MPN as defined by the World Health Organization (WHO) criteria (2008).

  3. For subjects enrolled in the AML cohort:

    1. Documented pathological evidence of AML, as defined by WHO criteria (2008)
    2. Refractory to previous induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
  5. Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures (including bone marrow assessments).
  6. At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 14. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.
  7. Acceptable liver function:

    1. Total bilirubin upper limit of normal (ULN).
    2. AST (SGOT) and ALT (SGPT) 1.5 x ULN.
  8. Acceptable renal function with serum creatinine 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease formulas.
  9. Female subjects must be:

    1. Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); or
    2. If of child-bearing potential, subject must use a highly effective method of contraception, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence. Both females and male subjects with female partners of child-bearing potential must agree to use a highly effective method of contraception for 2 weeks prior to screening, during, and at least 28 days after last dose of trial medication for females and 90 days for males. Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of trial medication.
    3. And, not breast feeding at any time during the study.
  10. Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria:

  1. Neoplasia harbours RAS mutation (NRAS mutant, KRAS mutant or double mutant)
  2. Acute promyelocytic leukemia or Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis)
  3. Clinically active CNS leukemia
  4. CMML with t(5;12) that have not yet received imatinib.
  5. Participation in any interventional study within 1 week of randomization or 5 half-lives of the prior treatment agent (whichever is longer).
  6. Ongoing treatment with an anticancer agent for CMML, MDS/MPN or AML not contemplated in this protocol. Subjects on a stable dose of hydroxyurea for at least 2 weeks prior to Cycle 1 Day 1 may continue on hydroxyurea until Cycle 1 Day 14.
  7. Hematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Cycle 1 Day 1.
  8. Concurrent use of granulocyte macrophage colony-stimulating factor (GM-CSF).
  9. Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor.
  10. Active coronary artery disease requiring treatment, myocardial infarction within the prior year, New York Heart Association grade III or greater congestive heart failure, cerebro-vascular attack within the prior year, or current serious cardiac arrhythmia requiring medication except atrial fibrillation.
  11. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
  12. Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
  13. Active and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.
  14. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
  15. The subject has legal incapacity or limited legal capacity.
  16. Significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02807272


Contacts
Layout table for location contacts
Contact: Jeanne Britt 678-777-0686 medicalaffairs@kuraoncology.com

Locations
Layout table for location information
United States, Arizona
Mayo Clinic Arizona Recruiting
Scottsdale, Arizona, United States, 85054
United States, Florida
Mayo Clinic Florida Recruiting
Jacksonville, Florida, United States, 32224
H. Lee Moffitt Cancer Center & Research Institute, Inc. Recruiting
Tampa, Florida, United States, 33612
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21231
United States, Minnesota
Mayo Clinic Rochester Recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Kura Oncology, Inc.
Investigators
Layout table for investigator information
Principal Investigator: TBD TBD, TBD

Layout table for additonal information
Responsible Party: Kura Oncology, Inc.
ClinicalTrials.gov Identifier: NCT02807272    
Other Study ID Numbers: KO-TIP-004
First Posted: June 21, 2016    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tipifarnib
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases
Hematologic Diseases
Antineoplastic Agents